within Pharmacolibrary.Drugs.ATC.D;

model D05BX51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.002,
    adminDuration  = 600,
    adminMass      = 240 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.07,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004166666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D05BX51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fumaric acid derivatives in combination (ATC D05BX51) are mainly used for the treatment of moderate to severe plaque psoriasis and sometimes for multiple sclerosis. The combinations typically include dimethyl fumarate and monoethyl fumarate salts, sometimes with other excipients. The drug is approved and in use predominantly in Europe for psoriasis.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic profile for healthy adult volunteers after oral administration of standard combination fumaric acid esters (dimethyl fumarate and monoethyl fumarate salts), as direct pharmacokinetic data for the specific combination formulation is not available in referenced publications. Values are based on typical profiles of dimethyl fumarate and extrapolations from monotherapy studies.</p><h4>References</h4><ol><li><p>Sticherling, M, et al., &amp; Mrowietz, U (2011). Therapy of psoriasis in childhood and adolescence - a German expert consensus. <i>Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG</i> 9(10) 815–823. DOI:<a href=&quot;https://doi.org/10.1111/j.1610-0387.2011.07668.x&quot;>10.1111/j.1610-0387.2011.07668.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21585653/&quot;>https://pubmed.ncbi.nlm.nih.gov/21585653</a></p></li><li><p>Bayard, W, et al., &amp; Joshi, R (1987). [Peroral long-term treatment of psoriasis using fumaric acid derivatives]. <i>Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete</i> 38(5) 279–285. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3112040/&quot;>https://pubmed.ncbi.nlm.nih.gov/3112040</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D05BX51;
